In addition, the relationship between the CALLY index and key molecular markers in CRC, such as MSI status, KRAS/NRAS, and BRAF mutations, could provide deeper insight into the biological underpinnings of CRC and its response to treatment. The gene discussed is BRAF; the disease is colorectal carcinoma.